TinaAAyeniMD

PubMed

• 5 citations
  Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer.
  Eati Basal, Tina A. Ayeni, Qing Zhang, Carrie L. Langstraat, Patricia K. Donahoe, David Pépin, Xueqian Yin, E. Leof, William A. Cliby> ;Current Molecular Medicine. 2016 Feb 29
• 2 citations
  Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach?
  Tina A. Ayeni, Mariam M. AlHilli, Jamie N. Bakkum-Gamez, Andrea Mariani, Michaela E. McGree, Amy L. Weaver, William A. Cliby, Gary L. Keeney, Karl C. Podratz, Sean C. ...> ;International Journal of Gynecological Cancer. 2015 Jan 1
• 66 citations
  Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas
  Tina A. Ayeni, Jamie N. Bakkum-Gamez, Andrea Mariani, Michaela E. McGree, Amy L. Weaver, Michael G. Haddock, Gary L. Keeney, Harry J. Long, Sean C. Dowdy, Karl C. Podratz> ;Gynecologic Oncology. 2013 Jun 1
• 6 citations
  Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma
  Tina A. Ayeni, Jamie N. Bakkum-Gamez, Andrea Mariani, Michaela E. McGree, Amy L. Weaver, Mariam M. AlHilli, Janice R. Martin, Gary L. Keeney, Sean C. Dowdy, Karl C. Po...> ;Gynecologic Oncology. 2013 Jan 1
• 29 citations
  Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
  Deanna Teoh, Tina A. Ayeni, Jennifer M. Rubatt, David J. Adams, Lisa A. Grace, Mark D. Starr, William T. Barry, Andrew Berchuck, Susan K. Murphy, Angeles Alvarez Secord> ;Gynecologic Oncology. 2011 Apr 1
• 81 citations
  Outcomes in surgical stage I uterine papillary serous carcinoma
  Laura J. Havrilesky, Angeles Alvarez Secord, Victoria L. Bae-Jump, Tina A. Ayeni, Brian Calingaert, Daniel L. Clarke-Pearson, Andrew Berchuck, Paola A. Gehrig> ;Gynecologic Oncology. 2007 Jun 1
• Join now to see all